AI assistant
Sending…
Grace Therapeutics, Inc. — Director's Dealing 2017
Feb 22, 2017
34679_dirs_2017-02-22_a2922eb4-069e-4e68-9660-36895f10f8dd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Acasti Pharma Inc. (ACST)
CIK: 0001444192
Period of Report: 2017-02-21
Reporting Person: Canan John (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Shares (Common Shares) | 5000 | Direct |
| Class A Shares (Common Shares) | 35000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants | $2.15 | 2022-02-21 | Class A Shares (Common Shares) (17500) | Direct |
More from Grace Therapeutics, Inc.
Regulatory Filings
2026
Apr 27
Regulatory Filings
2026
Apr 23
Major Shareholding Notification
2026
Feb 17
Interim / Quarterly Report
2026
Feb 12
Regulatory Filings
2026
Feb 12
Major Shareholding Notification
2026
Jan 28
Director's Dealing
2026
Jan 12
Director's Dealing
2026
Jan 12
Director's Dealing
2026
Jan 12
Director's Dealing
2026
Jan 12